Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04285346 · ClinicalTrials.gov registry record · Phase 2
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
A Phase 2 study, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT04285346 is a Phase 2 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT04285346, a Phase 2 study, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week treatment period.
Interventions
- DRUG Ganaxolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-04-08 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04285346
The ClinicalTrials.gov registry entry for NCT04285346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ganaxolone is the first listed.
NCT04285346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04285346 about?
NCT04285346 is a clinical study titled "Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)". To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week treatment period.
What is the current status of trial NCT04285346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2020-04-08. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT04285346?
The interventions under investigation include: Ganaxolone (DRUG).
Who is sponsoring clinical trial NCT04285346?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.